These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 26845923)

  • 21. Hepatitis C: a new horizon.
    Chang KM
    Gastroenterology; 2006 Dec; 131(6):1667-8. PubMed ID: 17188957
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of microRNAs in hepatitis C virus RNA replication.
    Conrad KD; Niepmann M
    Arch Virol; 2014 May; 159(5):849-62. PubMed ID: 24158346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors.
    Chen D; Cai J; Yin J; Jiang J; Jing C; Zhu Y; Cheng J; Di Y; Zhang Y; Cao M; Li S; Peng Z; Hao X
    Future Med Chem; 2015; 7(5):561-70. PubMed ID: 25921398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bringing the Hepatitis C Virus to Life.
    Cell; 2016 Sep; 167(1):39-42. PubMed ID: 27634322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus and microRNAs: miRed in a host of possibilities.
    Singaravelu R; Russell RS; Tyrrell DL; Pezacki JP
    Curr Opin Virol; 2014 Aug; 7():1-10. PubMed ID: 24721496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
    van der Ree MH; van der Meer AJ; de Bruijne J; Maan R; van Vliet A; Welzel TM; Zeuzem S; Lawitz EJ; Rodriguez-Torres M; Kupcova V; Wiercinska-Drapalo A; Hodges MR; Janssen HL; Reesink HW
    Antiviral Res; 2014 Nov; 111():53-9. PubMed ID: 25218783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
    Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Worth the wait. New, more effective therapies for hepatitis C are on the way.
    Learned J
    Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7.
    Zhu B; Wei XX; Wang TB; Zhou YC; Liu AM; Zhang GW
    Arch Virol; 2015 Aug; 160(8):2043-50. PubMed ID: 26071245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular virology of hepatitis C].
    Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HCV versus HIV drug discovery: Déjà vu all over again?
    Watkins WJ; Desai MC
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2281-7. PubMed ID: 23489621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influence of miR-122 on IFN-α treatment for HCV infection].
    Li SJ; Chen Z; Zhu HH
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 40(6):588-92, 652. PubMed ID: 22190517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.
    Beard MR; Ffrench R; Gowans EJ; Helbig KJ; Eyre NM; Douglas MM; Grebely J; Ahlenstiel G; Locarnini S; George J; Shackel NA; White PA; Thompson AJ; Drummer HE
    Gastroenterology; 2014 Jul; 147(1):e1-4. PubMed ID: 24861641
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758.
    Yang Q; Fu S; Wang J
    Arch Virol; 2014 Nov; 159(11):2997-3003. PubMed ID: 25008898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant use of direct-acting antiviral agents and chemotherapy in hepatitis C virus reactivation.
    Huang IH; Hsieh TY; Lin JC; Huang TC
    J Formos Med Assoc; 2018 Nov; 117(11):1034-1035. PubMed ID: 30173930
    [No Abstract]   [Full Text] [Related]  

  • 40. Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection.
    Uprichard SL
    Hepatology; 2014 May; 59(5):2043-6. PubMed ID: 24277664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.